Recombinant Endoglin-Single-Chain Variable Fragment/ Induced Protein 10 Fusion Protein Potently Boosts the Anti-Tumor Efficacy of Adoptively Transferred TRP2-Specific CD8 CD28 Cytotoxic T Lymphocytes in Mice.

In this research, we studied the therapeutic efficacy of a newly designed fusion protein containing Endoglin single-chain variable fragment and IP10 (Endoglin-scFv/IP10), together with our recently generated TRP2-specific CD8 CD28 CTLs (CD8 CD28 CTLs) in controlling melanoma growth in mice. The recombinant Endoglin-scFv/IP10 was expressed in , purified by affinity chromatography, and characterized for its chemotactic movement and immunoreactivity with endoglin-expressing cells. , melanoma xenografts were established in mice (C57BL/6) using B16F10 cells.